TMCnet News

Fallopian Tube Cancer - Pipeline Review, H1 2016 - Key Players are Novartis, Pfizer & Boston Biomedical - Research and Markets
[May 27, 2016]

Fallopian Tube Cancer - Pipeline Review, H1 2016 - Key Players are Novartis, Pfizer & Boston Biomedical - Research and Markets


Research and Markets has announced the addition of the "Fallopian Tube Cancer - Pipeline Review, H1 2016" report to their offering.

The report provides comprehensive information on the therapeutics under development for Fallopian Tube Cancer, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Fallopian Tube Cancer and features dormant and discontinued projects.

Our report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Reasons to buy:

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies.
    • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Identify and understand important and diverse types of therapeutics under development for Fallopian Tube Cancer.
  • Identify potential new clients or partners in the target demographic.
  • Develop strategic initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics.
  • Devise corrective measures for pipeline projects by understanding Fallopian Tube Cancer pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.


Companies Mentioned:

  • AbbVie Inc.
  • Amgen Inc.
  • Astex Pharmaceuticals, Inc.
  • AstraZeneca Plc
  • Atara Biotherapeutics, Inc.
  • Bayer AG
  • Boehringer Ingelheim GmbH
  • Boston Biomedical, Inc.
  • Caladrius Biosciences, Inc.
  • Celldex Therapeutics, Inc.
  • Celsion Corporation
  • Cerulean Pharma, Inc.
  • Clovis Oncology, Inc.
  • Corcept Therapeutics Incorporated
  • Critical Outcome Technologies Inc.
  • CTI (News - Alert) BioPharma Corp.
  • Dr. Reddy's Laboratories Limited
  • EirGenix Inc.
  • Eli Lilly and Company
  • ImmunoGen, Inc.
  • Johnson & Johnson
  • Novartis AG
  • Pfizer Inc.
  • Vascular Biogenics Ltd.
  • VentiRx Pharmaceuticals, Inc.
  • Vyriad
  • (40+ More)

For more information visit http://www.researchandmarkets.com/research/m5f4x6/fallopian_tube



[ Back To TMCnet.com's Homepage ]